Biogen loses CMO, neuromuscular leader; John Hood adds president, CFO at Endeavor BioMedicines

15 Mar 2024
endpts.com
Executive ChangeDrug Approval
→ Biogen chief medical officer Maha Radhakrishnan is out after four years “as of March 1,” a spokesperson tells Peer Review. Biogen didn’t draw up a press release for her departure, but a board appointment at NYSE newcomer Alto Neuroscience was the first indication that Radhakrishnan decided to leave. In her second time around at the big biotech, the Alzheimer’s drug Aduhelm flamed out, while the Eisai -partnered follow-up Leqembi earned a full FDA approval as Eli Lilly waits on the sidelines with donanemab . From 2013-16, Radhakrishnan was Biogen’s VP, US medical and VP, Europe and Canada medical before her tenure at Bioverativ and Sanofi . “Maha made many important contributions to Biogen and the patients we serve — most notably establishing our framework for early patient access, enabling many patients to benefit from important and potentially lifesaving new therapies globally,” a Biogen spokesperson said.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-
Targets
-
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.